A Randomization, Double-blind, Parallel, Multicenter-Phase 2a Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to primarily investigate the safety and tolerability of EB-203 by dose in patients with neovascular Age-related Macular Degeneration (nAMD), and to secondarily evaluate the clinical efficacy. Subject to Adults aged 50 years or older and Neovascular age-related macular degeneration (nAMD)

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• Adults aged 50 years or older

• Subjects with a best corrected visual acuity (BCVA) score between 25 and 73, measured by the Early Treatment of Diabetic Retinopathy Study(ETDRS) chart, at a distance of 4 m during the screening (equivalent to 20/40 to 20/320 in the Snellen chart)

• Subjects who voluntarily signed the informed consent form (ICF) after receiving the information on this study

Locations
Other Locations
Republic of Korea
Busan Paik Hospital, Inje University
RECRUITING
Busan
Pusan National University Hospital
RECRUITING
Busan
Yeungnam University Medical Center
RECRUITING
Daegu
Kim's Eye Hospital
RECRUITING
Seoul
Seoul National University Hospital
RECRUITING
Seoul
Contact Information
Primary
SUYEON KIM
suyeon@eyebiokorea.com
1047070314
Backup
YUNSEOK CHO
yscho@eyebiokorea.com
70-4129-7497
Time Frame
Start Date: 2024-08-01
Estimated Completion Date: 2026-01
Participants
Target number of participants: 50
Treatments
Experimental: Group A
EB-203 2% QID
Experimental: Group B
EB-203 4% QID
Related Therapeutic Areas
Age-Related Macular Degeneration (ARMD)
Late-Onset Retinal Degeneration
Sponsors
Leads: EyebioKorea, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)

A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)

Enrollment Status: Recruiting
Publish Date: April 04, 2024
Intervention Type: Genetic

A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD

A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD

Enrollment Status: Recruiting
Publish Date: July 09, 2024
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2

A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants With Neovascular Age-Related Macular Degeneration

A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants With Neovascular Age-Related Macular Degeneration

Enrollment Status: Recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View All